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TO TELL OR NOT TO TELL: THE SCOPE OF
PHYSICIAN-PATIENT CONFIDENTIALITY
WHEN RELATIVES ARE AT RISK OF
GENETIC DISEASE
Andrea Sudell*

INTRODUCTION

The Human Genome Project and related advances in genetic research
and biotechnology reveal new information about the role of genes in
determining human traits and predisposition to certain diseases.'
Knowledge about the effects of deoxyribonucleic acid (DNA) variations
in individuals may lead to revolutionary new ways to diagnose, treat and
2
prevent the thousands of disorders affecting the human race.
However, moral and legal dilemmas surface surrounding the increased
ability to identify human genes and link them to inherited traits and
diseases.3 Specifically, physicians may face situations in which their
interest in protecting third parties conflicts with the confidentiality
4
element of the physician-patient relationship.
While physicians are
obligated both ethically and legally to keep information about their
patients confidential, the scope of this duty has long been debated.5 The
availability of genetic information creates a new dispute about the

* J.D. Candidate 2002, The Catholic University of America, Columbus
School of Law; B.S.N. 1997, Georgetown University. The author would like to
thank her parents for their unconditional support and encouragement.
1. See Oak Ridge Nat'l Laboratory, ABOUT THE HUMAN GENOME PROJECT, at
http://www.ornl.gov/hgmis/project/about.html (last visited Dec. 18, 2001).
2. See id.
3. See id.
4. See Lori B. Andrews, Torts and the Double Helix: MalpracticeLiability for
Failureto Warn of Genetic Risks, 29 HOUs. L. REV. 149, 180 (1992).
5. See Alissa Brownrigg, Note, Mother Still Knows Best: Cancer-Related Gene
Mutations, Familial Privacy, and a Physician'sDuty to Warn, 26 FORDHAM URB.
L.J. 247, 248 (1999).
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limitations that physician-patient confidentiality places on disclosure.
For example, in cases where confidential information affects the health of
a patient's relatives, the argument exists that
physicians
have a duty to
• ,
7
warn relatives with or without their patients' consent.
This Comment argues that patient confidentiality is not absolute and
that disclosure to third parties is permissible under certain circumstances.
Part I provides an overview of genetic testing. Part II discusses case law
and state statutes concerning the conflict between physician-patient
confidentiality and the conflicting duty to warn. Part III reviews the
confidentiality requirement specifically with respect to genetic
information. Part IV proposes guidelines for circumstances when
disclosure by the physician to the patient's relatives is warranted. This
Comment concludes that a physician's privilege to warn third parties
about a patient's genetically transferable disease extends to some cases
where relatives are at risk. In deciding whether to disclose, a physician
must weigh the harm of failing to disclose against the harm of disclosure.
This balancing should be employed on a case-by-case basis.
I. AN OVERVIEW OF GENETIC RESEARCH
A. Genetic Testing

A genome
is composed of an organism's entire DNA, including its
8
genes. Genes carry the information to create all of the proteins required
by every organism.9 These proteins determine, among other things, how
the organism looks, how the body fights infection and how it behaves.'0
Essentially, genetic information provides the framework for an
individual's traits."

6. See The American Society of Human Genetics Social Issues Subcommittee
on Familial Disclosure, ASHG Statement: Professional Disclosure of Familial
Genetic Information, 62 AM. J. HUM. GENETICS 474, 476 (1998), available at
http://www.faseb.org/genetics/ashg/policy/pol-29.htm [herinafter ASHG].

7. See id.
8. See Oak
INFORMATION,

Ridge

Nat'l

Laboratory,

GENE

HUMAN

GENOME

PROJECr

TESTING,

http://www.ornl.gov/hgmis/medicine/genetest.html (last visited Dec. 18, 2001).

9. See id.
10. See id.
11. See id.

at
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Gene tests, or DNA-based tests, are utilized to check for genetic
disorders. The newest and most sophisticated of these tests involves
direct examination of the DNA molecule. 3 Some tests clarify a diagnosis
and direct the physician toward appropriate treatments. 14 Other tests,
however, identify parents at risk of having children with diseases or
identify people at high risk for developing certain conditions that may be
preventable." For example, monitoring those at risk of inheriting a gene
for familial colon tumors" allows for early detection and removal of colon
growths, and thus saves many lives." Within the foreseeable future, a
simple diagnostic gene test for iron-storage disease will enable physicians
to treat this presently fatal condition. 18
However, the practice of gene testing is the subject of some debate) 9
Most controversial is genetic testing for adult-onset disorders such as
Alzheimer's disease, 2° Huntington disease,"2 and autosomal dominant
polycystic kidney disease. 22 Targeted at healthy, pre-symptomatic
individuals with a strong family medical history for the disorder, these
tests only reveal one's probability of developing the disorder.23
12. See id.

13.
14.
15.
16.

See id.
See id.
See id.
Clinically referred to as familial adenomatous polyposis. Defined as the

"[p]resence of several polyps.. .affecting more members of the same family than
can be accounted for by chance." Stedman's Medical Dictionary (26th ed.
Williams & Wilkins 1995) at 627 and 1406.
17. GENE TESTING, supra note 8.
18. See id.
19. See id.
20. "[P]rogressive
mental
deterioration
manifested by loss of
memory... confusion; disorientation. Begins in late middle life and results in
death in 5-10 years." Stedman's Medical Dictionary (26th ed. Williams & Wilkins
1995) at 492.
21. "[A] progressive disorder usually beginning in young to middle age,
consisting of a triad of choreoatheotsis, dementia, and autosomal dominant
inheritance." Id. at 333.
22. "[A] progressive disease characterized by formation of multiple cysts of
varying size scattered diffusely throughout both k[idneys], resulting in
compression and destruction of k[idney]... there are two major types.. .2) with
onset in adulthood, with autosomal dominant inheritance." Id. at 919.
23. GENE TESTING, supra note 8.
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Accordingly, certain people who carry the disease-associated gene
mutation will never actually develop the disease. 24 As with all medical
testing, there also exists the possibility for laboratory errors.25 However,
due to the novelty and sophistication of genetic tests, many in the medical
community believe that the negative implications 26 of the test may
outweigh its benefits.27 Although early detection may be helpful in
preventing a disease or ameliorating its effects, pursuing genetic testing
can be worrisome for those in jeopardy of a genetic disorder. The
prospect of learning that one suffers from a disease is daunting. Further,
the potential exists for genetic knowledge to be used as a tool for
28
discrimination or manipulation.
B. The Human Genome Project
The United States Human Genome Project formally began in 1990 and
was originally projected to last fifteen years. 29
However, rapid
technological advances accelerated the expected completion date to
2003.30 Today, scientists are well on their way to completing the entire
human genome sequence.3'
Recent analyses by two rival groups32

24. See id.
25. See id.
26. See id. Negative implications include uncertainties surrounding test
interpretation, the current lack of available medical options for these diseases, the
test's potential for provoking anxiety, and risks of discrimination and social
stigmatization.
27. See Smith et al., Early Warning, in CASES AND ETHICAL GUIDANCE FOR
Ind. U. Press 1998). Genetic

PRESYMPTOMATIC TESTING IN GENETIC DISEASES 1

information "may enable individuals to avoid illness through early intervention
and, potentially, gene therapy."
28. For example, based on genetic information about susceptibility to disease,
employers and insurance companies might deny employment and/or insurance
benefits. See Tony McGleenan, Rights to Know and Not to Know: Is There a Need
for a Genetic Privacy Law? in THE RIGHT TO KNOW AND RIGHT NOT TO KNOW 43,

50 (Ruth Chadwick et al. eds., 1997).
29. ABOUT THE HUMAN GENOME PROJECT, supra note 1.

30. See id.
31. See OAK RIDGE NAT'L LABORATORY, FREQUENTLY ASKED QUESTIONS,
at http://www.ornl.gov/hgmis/project/about.htm (last visited Dec. 18, 2001). ("A

rough draft of the human genome was completed in June 2000. Efforts are still
underway to complete the finished, high-quality sequence.").
32. See Nicholas Wade, Long-Held Beliefs Are Challenged by New Human
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revealed their first interpretations of the human genome sequence."
These gene sequences create a genetic map that helps predict and/or
From these
determine one's propensity to develop certain diseases.'
findings, biologists hope to pinpoint the variant genes that underlie many
common diseases." This will enable physicians to recognize and treat a
disease at its genetic root. 36
Although an innovative scientific advancement, the Human Genome
Project also leads to complex ethical, legal and social concerns.37 These
concerns include: preservation of privacy;18 introduction and use of new
genetic tests; 39 and outside use of genetic information by various
professionals and groups who may deal with, or be influenced by, such

Genome Analysis, N.Y. TIMES, Feb. 12, 2001, at A20. The two groups are Celera
Genomics and the International Human Genome Sequencing Consortium, a
group of academic centers financed largely by the National Institutes of Health
and the Wellcome Trust of London. Id.
33. See id. ("Though the two sides differ strongly as to which has the better
strategy for decoding the genome's sequence of 3.2 billion DNA units, they largely
agree in their interpretations of it.").
34. See id.
35. See id.
36. See id.

37. See ABOUT THE HUMAN GENOME PROJECT, supra note 1 (stating that the
Project's goals include: identification of all the approximately 100,000 genes in
human DNA; determining the sequences of the three billion chemical bases that
make up human DNA, storing this information in databases; developing faster,
more efficient sequencing technologies; developing tolls for data analysis; and
addressing the ethical, legal, and social issues ("ELSI") that may arise from the
project).
38. See generally Social Policy Research Prioritiesfor the Human Genome
Project, in GENE MAPPING 269 (George J. Annas and Sherman Elias eds., 1992).
Specifically, problems arise in maintaining the confidentiality of patient's genetic
information with respect to informing other family members of genetic traits that
they may carry.
39. See id. at 271. The authors point out that this issue contains numerous
sub-issues. The first sub-issue involves determining how the medical standard of
care should be set. This includes establishing when and who should determine the
point at which new screening should become routine, and at what age it should
take place. The next sub-issue concerns what information a patient should be
given regarding screening tests, as well as how, when and who should present the
information.
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information.40
The Human Genome Project is unique in that it is the first large
scientific endeavor to specifically address the moral, legal and humanistic
concerns raised by the project.4' To support the work of the National
Human Genome Research Institute (NHGRI), the Department of Energy
(DOE) created the Ethical, Legal and Social Implications Program
(ELSI). 42 The focus of the ELSI Program is to study genetic privacy and
to foster education in genome science.43 In carrying out these goals, DOE
and NHGRI support workshops for U.S. judges who decide cases in
44
which genetic information is introduced. The group has also studied a
draft genetic privacy law.45
C. The Impact of Genetic Research on Society
Advances in genetic research raise questions as to the degree to which
genetic information should be protected. The utilization of this
information stretches the concept of privacy law.46 In disclosing genetic
information to patients, medical professionals must consider potential
harms.
In addition, they must consider to whom genetic information
may be disclosed. 8
To properly resolve this dilemma, one must understand the interests of

40. See
RESEARCH,

LIFE SCIENCE DISVISION OFFICE, BIOLOGICAL AND ENVIRONMENTAL
ETHICAL,

LEGAL

AND

SOCIAL

IMPLICATIONS

(ELSI),

at

http://www.er.doe.gov/production/ober/elsi.html (last visited Dec. 18, 2001); see
George J. Annas and Sherman Elias, Social Policy Research Prioritiesfor the
Human Genome Project,in GENE MAPPING at 273 (Oxford University Press 1992)
("It is likely that both employers and insurance companies will want to use largescale genetic screening of applicants when the technology becomes relatively
inexpensive... The challenge is to prevent the products of the Human Genome
Project from becoming just another mechanism for discrimination.").
41. ABOUT THE HUMAN GENOME PROJECT, supra note 1.
42. ETHICAL, LEGAL AND SOCIAL IMPLICATIONS (ELSI), supra note 40.
43. See id.
44. See id.
45. See id.
46. McGleenan, supra note 28, at 46.
47. See id.
48. See Jeffery W. Burnett, A Physician'sDuty to Warn a Patient'sRelatives of
a Patient's Genetically InheritableDisease, 36 Hous. L. REV. 559, 560-61 (1999).
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third parties who desire access to this genetic information. Potential
third parties are varied and include insurance companies, employers and
family members.5" In the hands of both groups, genetic information could
The insurance industry could use this
lead to discrimination."
information as a tool by which to measure one's life expectancy and
12
propensity for illness in order to set insurance rates. Genetic
information, which might affect employment decisions, could also aid
employers in determining which employees are predisposed to certain
diseases.53 Of special importance are third parties who are family
members that would be placed at risk by this information. While genetic
information should be considered medical information, it is both
individual and familial in nature.55 The patient is entitled to keep personal
medical information private. However, since it is genetically transferable,
it may impact other family members. This creates a conflict between
physicians' confidentiality obligations to their patients and the physicians'
ethical duty to warn the at-risk relatives.
Well before the emergence of any legal requirements, physicians had
an ethical obligation to protect personal information about their
patients.57 Since ancient times, the Hippocratic Oath has directed doctors

49. See id. at 561.

50. See id.
51. See Paul Recer, Gene Map May Create Discrimination,WASH. POST, Feb.
12, 2001, at A5. ("Without adequate safeguards, the genetic revolution could
mean one step forward for science and two steps backward for civil rights...
[m]isuse of genetic information could create a new underclass: the genetically less

fortunate.").
52. Burnett, supra note 48, at 561; see also Recer, supra note 51, at A5 ("[Sen.
Bill] Frist and Sen. Olympia Snowe are introducing legislation that would prevent
insurance companies from requiring genetic testing and ban the use of genetic
information to deny coverage or to set rates.").
53. Burnett, supra note 48, at 561; see also Recer, supra note 51, at A5 ("A
survey of 2,133 employers this year by the American Management Association
found that seven are using genetic testing for either job applicants or
employees....").
54. Burnett, supra note 48, at 561.

55. See id.
56. See id.
57. See generally Brownrigg, supra note 5, at 247 (1999) (discussing the
Hippocratic Oath's continued importance as a "tenet of medical care today.").
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to refrain from divulging information about their patients." This ethical
position on physician-patient confidentiality remains intact today. 9
With respect to medical information, the right of privacy affords
protection of personal data and affirmation of confidentiality.6
As

genetic information is considered medical information, it is protected by
the legal and ethical principles of confidentiality existing within the
physician-patient relationship.61 Traditionally, confidentiality in the
physician-patient relationship was absolute and therefore barred
physicians
from disclosing any genetic information to their patients'
• 62
relatives. Health care providers also had an ethical duty not to breach
patient confidentiality.63 However, as with legal duty, codes of medical
ethics provide exceptions to permit physicians to disclose otherwise
confidential information. 64 One such exception occurs where a known
65
third party is at risk .
D. Ethical Considerations
Today, four ethical alternatives to this strict confidentiality requirement
6
have been proposed as applicable in certain situations. First, the 1983
President's Commission for the Study of Ethical Problems in Medicine
and Biomedical and Behavioral Research states that where a patient

58. See Oath of Hippocrates, reprinted in Barry R. Furrow et al., BIOETHICS:
HEALTH CARE LAW AND ETHICS (3d ed. 1997) ("[F]or the benefit of my
patients... I will not divulge ... all that should be kept secret.").
59. Id. ("A physician shall ... safeguard patient confidences within the
constraints of the law.").

60. ASHG, supra note 6, at 747.
61. See id.

62. See id.
63. See id.
64. See id. at 477 (noting "that the Code of Ethics of the Canadian Medical
Association [155(8) CAN. MED. Assoc. J. 1176A (1996)] permits a breach of a
patient's right to confidentiality 'when the maintenance of confidentiality would
result in a significant risk of harm to others.' In contrast, the Code of Ethics of the
American Medical Association [Fundamental Elements of the Patient-Physician
Relationship, AMA Current Options 624 (1996)] does not refer to risk of harm but
restricts itself to disclosure 'need[ed] to protect the welfare of the individual or the
public interest."').

65. See id.
66. See id.
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refuses, health care professional disclosure to at-risk family members is
permissible when:
(1) reasonable efforts to elicit voluntary consent to disclosure
have failed; (2) there is a high probability that harm will occur if
the information is withheld, and the disclosed information will
actually be used to avert harm; (3) the harm that would result to
identifiable individuals would be serious; and (4) appropriate
precautions are taken to ensure that only the genetic
information needed •for
diagnosis
and/or treatment of the
•
67
disease in question is disclosed.
The second proposal came from the American Institute of Medicine
Committee's 1994 report on assessing genetic risks. The Committe
adopted a position similar to that of the President's Commission. While
recommending that genetic information remain confidential, the report
suggested the possibility of disclosure to relatives in situations where the
genetic disorder is highly likely to present itself and is treatable or
preventable.69

Another suggested ethical position is a genetic "Miranda warning" that
would inform a patient, in advance, of circumstances which could result in
disclosure of genetic information to other family members.7" With notice
provided before testing, patients would receive forewarning about
possible disclosure regardless of their intentions to disclose.71 Consent by
the patient constitutes a waiver of the privilege and effectively preserves
the provider's ethical obligations. This position offers the advantage of
preserving the physician-patient relationship. However, it may also lead
to patient reluctance to undergo testing for fear that the results will be
67. See id. at 478 (stating the President's Commissionfor the Study of Ethical
Problems in Medicine and Biomedical and Behavioral Research, in SCREENING
AND COUNSELING FOR GENETIC CONDITIONS (U.S. Government Printing Office

1983)).
68. See id. (discussing the Institute of Medicine Committee's report on
Assessing Genetic Risks, in
HEALTH AND SOCIAL POLICY

ASSESSING

GENETIC RISKS: IMPLICATIONS

FOR

(National Academy Press 1994) "The committee

noted that the strongest case for warning by a health care professional would exist
where there is a high likelihood that the relative has the genetic defect, the defect

presents a serious risk to the relative and there is reason to believe that the
disclosure is necessary to prevent serious harm.").
69. See id.
70. See id.
71. See id.
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reported to anyone, especially family members, who may have a negative
reaction to the reported condition.
The fourth proposal suggests that an ethical standard imposing a duty
to warn could become obligatory. 72 While currently this duty is merely
permissible, an ethical duty may evolve into a professional and legal
standard absent any countervailing policy restraints.73
It is presumed that most properly informed patients would warn their
relatives of potential risks in order to ensure them early monitoring,
detection and treatment.7 4 At a minimum, health care professionals
should feel ethically obliged to inform patients of the implications of their
genetic test results and the potential risk to family members. 75 However,
under certain conditions, health care professionals ethically should be
permitted to breach patient confidentiality and disclose information to atrisk relatives.
II. LEGAL DUTY RECOGNIZING PATIENT CONFIDENTIALITY AND
THE PRIVILEGE TO DISCLOSE
The common law policy has been to encourage the free flow of
information in the physician-patient relationship. 6 This policy is based on
the advantages afforded to all by full disclosure of facts, which may bear
upon the diagnosis and treatment of the patient, however embarrassing or
harmful to the patient. 77 Courts have generally upheld or recognized the
right of a patient to recover damages from a physician for unauthorized
disclosure on invasion of privacy grounds. 78 With a few exceptions, courts
have also held or recognized that a patient may have a cause of action
79
against the physician for breach of the confidential relationship.
72. See id.
73. See id.
74. See id. at 475.
75. See id. at 474.
76. See Judy E. Zelin, J.D., Physician's Tort Liability for Unauthorized
Disclosure of Confidential Information About Patient, 48 A.L.R. 4th 668 (1986 &
West. Supp. 2000).
77. See id. § 2.
78. See id.
79. See id. §7. In a few jurisdictions, courts take the view that unauthorized
disclosure does not constitute breach of the confidential relationship, see e.g.,
Collins v. Howard, 156 F. Supp. 322 (D. Ga. 1957). However, in a number of
jurisdictions, it has been held or recognized that unauthorized disclosure may
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Statutes relating to testimonial privileges or licensing requirements may
provide a legal obligation for physicians to maintain patient
confidentiality. 80 In the 1920 case, Simonsen v. Swenson,"' the Nebraska
Supreme Court found a legal duty from a licensing statute that authorized
the revocation of medical licenses when a physician "'betray[ed] ...a
professional secret to the detriment of a patient."'2 This decision was
based on the public policy interest in maintaining physician-patient
confidentiality. 83 Some jurisdictions have also looked to doctor-patient
evidentiary statutes as indications of the underlying public policy
justification for allowing patients tort recovery when physicians violate
the duty of confidentiality. Recently, two South Carolina cases confirmed
the value placed on confidentiality within the physician-patient
relationship. The court recognized a cause of action in tort absent any
doctor-patient evidentiary privilege.4 Critical to both decisions was the
unique relationship of the doctor-patient relationship."
In the absence of a state statute, courts have applied contract theory to
find liability for breach of confidentiality. 86 In the 2000 case of Doe v.
Community Health Plan-Kaiser Corp.,87 the court held that a physician's
duty not to disclose a patient's confidential personal information "springs
from the implied covenant of trust and confidence that is inherent in the
physician-patient relationship," the breach of which is actionable as a
constitute breach of the confidential relationship, see e.g., Home v. Patton, 287 So.
2d 824 (Ala. 1973).
80. Id. at 699-700.
81. 177 N.W. 831, 832 (Neb. 1920).
82. Id. (quoting NEB. REV. STAT. § 2721 (1913)).
83. See id.
84. See Joseph Glenn White, Physicians' Liability for Breach of
Confidentiality: Beyond the Limitations of the Privacy Tort, 49 S.C. L. REV. 1271
(1998) (discussing South Carolina State Board of Medical Examiners v.
Hedgepath, 480 S.E.2d 724 (S.C. 1997), in which the South Carolina Supreme
Court ruled that physicians in South Carolina have a duty to maintain the
confidentiality of doctor-patient communications; and McCormick v. England, 494
S.E.2d 431 (S.C. Ct. App. 1997), in which the South Carolina Court of Appeals
recognized a cause of action in tort for breach of this duty of confidentiality).
85. See id.
86. See Horne v. Patton, 287 So.2d 824 (Ala. 1973) (identifying an implied
contractual duty preventing the disclosure of patient information as one of several
legal justifications for protecting patient confidentiality).
87. 709 N.Y.S.2d 215 (N.Y. App. Div. 2000).
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tort.n Other courts have found more than a mere contractual relationship
between patient and physician.' 9 In 1997, the Virginia Supreme Court in
Fairfax Hospital v. Curtis9° found that physicians, without authorization,
owe a duty to their patients not to disclose information gained in the
course of treatment. 9' In so holding, the court also noted that this duty
existed absent either a statutory command to the contrary or serious
danger to the patient. 92
Courts also recognize exceptions to the physician-patient confidential
relationship that require disclosure. 93
One such exception to the
confidentiality rule rests primarily on the concept of preventing
foreseeable harm to identifiable third parties. 94 In Tarasoff v. University
of California Board of Regents,95 the California Supreme Court
determined that psychotherapists who learn that their patient is likely to
cause serious and foreseeable harm to an identifiable third party, have a
duty to warn the endangered individual and take steps to protect that
individual from harm. 96
In addition, courts have created exceptions to the physician-patient
confidentiality rule to prevent harm. For example, a doctor may breach

88. Id. at 217.
89. See Sonia M. Suter, Whose Genes Are These Anyway?: FamilialConflicts
over Access to Genetic Information, 91 MICH. L. REV. 1854, 1872 (Tenn. 1993)
(discussing the Supreme Court of Oregon's decision in Humphers v. First
Interstate Bank, 696 P.2d 527 (Or. 1985), in which the court held the physician to a
nonconsensual duty of confidentiality, which "is determined by standards outside
the tort claim for its breach.").
90. 492 S.E.2d 642 (Va. 1997).
91. See id. at 644.
92. See id.
93. Zelin, supra note 76, §§ 14-19.
94. See Tarasoff v. Regents of University of California, 551 P.2d 334 (Cal.
1976) (en banc) (special relationship between physician and patient supports duty
of reasonable care to protect identifiable third party from harm threatened by
patient); see also Bradshaw v. Daniel, 854 S.W.2d 865 (1993) (holding that
physician had duty to warn patient's wife of her risk of contracting Rocky
Mountain Spotted Fever when he should have known patient had such disease);
Hoffman v. Blackmon, 241 So. 2d 752 (Fla. Dist. Ct. App. 1970) (finding physician
negligent for failing to diagnose tuberculosis in father, and failing to warn family
of child's risk of contracting such disease).
95. 555 P.2d 334 (Cal. 1976) (en banc).
96. Tarasoff, 551 P.2d at 340.
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confidentiality to protect the public from exposure to contagious disease,
or report an incidence of child neglect, an exception recognized in every
state. 98 Moreover, when informed that the child may be genetically
predisposed to disease, the failure of physicians to notify or arrange for
genetic testing of children may be viewed as analogous to neglect. This
situation would implicate the need for another privilege exception.
However, courts are split on whether to actually extend such an exception
to genetically inheritable diseases.

III. PHYSICIAN-PATIENT CONFIDENTIALITY WITH RESPECT TO
GENETIC INFORMATION

A. Case Law
Two leading cases demonstrate that courts are not settled on whether
to create a new exception to physician-patient confidentiality rules based
on disclosure of genetic information to help a patient's family avoid harm.
In Pate v. Threlkel,99 the Florida Supreme Court held that a physician does
not need to directly inform the patient's children of their genetic
predisposition to a disease.'0 Conversely, in Safer v. Estate of Pack,'° the
New Jersey Supreme Court rejected the argument that a physician's duty
to warn a patient's family members of a genetic disease is satisfied by
notifying only the patient. Instead, the court required that a doctor take

97. In Simonsen v. Swenson, 177 N.W. 831, 832 (Neb. 1920) (per curiam), the
court found that physicians should not be liable for disclosing information when
"necessary to prevent the spread of... disease."; see also N.Y. Pub. Health Law
2101 (McKinney 1993); N.Y. COMP. CODES R. & REGS. TIT. 10 2.10 (1997)
(allowing exceptions to the confidentiality requirement where patients are
diagnosed with communicable diseases). See also Alexander v. Culp, 705 N.E.2d
378 (8th Dist. Cuyahoga County 1997) (holding that a physician is not liable for
disclosing confidential information to a non-patient if the communication to the
non-patient was necessary for the welfare of the non-patient or the welfare of the
public).
98. See James T.R. Jones, Battered Spouses: Damage Actions Against NonReporting Physicians, 45 DEPAUL L. REV. 191, 212 ("By statute all states require
physicians to report known or suspected child abuse to specified authorities.").
99. 661 So.2d 278 (Fla. 1995).
100. See id. at 282.
101. 677 A.2d 1188 (N.J. Super. 1996).
102. See id. at 1192.
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reasonable steps to ensure that family members are notified of a genetic
disease. 03
1. Pate v. Threlkel

Heidi Pate, the adult daughter of a woman diagnosed with medullary
thyroid carcinoma, " a malignant cancer of the thyroid, received the same
diagnosis three years after her mother was treated.'0 5 Subsequently, Pate
filed a complaint against her mother's physicians for failure to warn of the
hereditary nature of the cancer.' °6 Not until she learned that she suffered
from this disease did Pate discover that her condition was genetically
inherited from her mother.1 7 Accordingly, Pate claimed that the doctors
should have been aware of the disease's hereditary quality and that the
physicians owed her mother a duty to warn her about testing her children
for the disease." This notice would have allowed Pate to monitor for the
cancer and take precaution that would have made a cure more probable
than not.' 9
The trial court dismissed the complaint due to lack of privity between
Pate and her mother's physicians."0 The appellate court agreed with the
rationale of the trial court in rejecting the idea that the familial
relationship justified extension of the physician's duty to certain family
members.'1 The court did, however, note that a physician's duty may
extend to third parties outside the physician-patient relationship when
there exists a "foreseeable zone of risk" to the third party.
However,
the court reasoned that Ms. Pate was not within this foreseeable zone of

103. See id.

104. Familial medullary thyroid carcinoma is a genetic disease, one in which
specific information carried by the genes causes the disease. Robert F. Gagel,
M.D. & Zoila Torres Feldman, R.N., M.S., FamilialMedullary Thyroid Carcinoma
A
GUIDE
FOR
AFFECTED
FAMILIES,
at
http://endrcr06.mda.uth.tmc.edu/educational/mtc.htm (last visited Dec. 18, 2001).
105. See Pate, 661 So.2d at 279.
106. See id.
107. See id.
108. See id.
109. See id.

110. See id. at 279-80.
111. See id.
112. Id.
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risk and therefore no duty towards her existed."
The Florida Supreme Court reversed the lower courts' decisions,
holding that the physician had a duty to warn Pate's mother of the
cancer's genetically transferable nature" 4 The court recognized that
Florida's statutory definition of duty provided that a claimant has the
burden of proving that the alleged actions of the health care provider
represented a breach of the prevailing professional standard of care for
that provider."' The court accepted the plaintiff's allegation that the
prevailing standard of care commanded that the patient receive a warning
about the genetic inheritability of her disease."' The court also noted that
Pate satisfied the privity requirement because she could be considered an
intended third party beneficiary of the prevailing standard of care. 117
Further, the court noted that a patient's children do fall under the
requisite
zone of foreseeable risk encompassing the physician's duty to
118
warn. Specifically, the court held that the physicians' duty to warn their
patients' children of their predisposition to a genetically inheritable
disease is satisfied by warning only the patient."9 The court reasoned
that, based• on
the
•
• advice
120 of their physicians, patients are responsible for
warning their children. The court stated that if a physician were to warn
the third party directly, he would breach his duty of confidentiality to his
patient.
The court also noted that the duty to warn a third party was
122
impractical and burdensome.
2. Safer v. Estate of Pack
Donna Safer was diagnosed with cancerous polyposis,' 23 a cancer of the
113. See id.
114. See id.
115. See id.

116. See id. at 281.
117. See id. at 282.
118. See id.

119. See id.
120. See id.
121. See id.

122. See id. ("To require the physician to seek out and warn various members
of the patient's family would often be difficult or impractical and would place too
heavy a burden on the physician.").

123. Defined in Stedman's, supra note 16, at 1424, as "Several cancerous
polyps."
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colon, • thirty-four
years after her father was treated for the same
. 124
condition. Safer and her husband filed a complaint against the estate of
her father's treating physician.12 ' The complaint alleged that the physician
knew of the hereditary nature of cancerous polyposis, and was therefore
under a duty to warn relatives at risk.12 Safer argued that if she had been
127
warned, the worst effects of her disease could have been avoided.
Relying on the appellate court's decision in Pate, the trial court held
that the physician did not have a duty to warn his patient's child of genetic
risk for disease. The court determined that privity impeded the action
due to the lack of a patient-physician relationship between the child and
the doctor.9 Because there was no risk to public health, the court
reasoned that no exception to the privity requirement existed. 30 The
Court found that the duty to warn in this case differed from those
involving contagious or infectious disease because the harm already exists
within the child instead of being introduced by a patient warned to stay
131
away.
132
The Superior Court of New Jersey reversed the trial court's decision.
It acknowledged that a physician has a duty to warn the patient as well as
members of the patient's immediate family who may be adversely affected
by a failure to warn. WThe court maintained that no significant difference
existed between the threat of infection from contagious disease and the
threat posed by genetic disease when a physician fails to disclose the
condition. 34 The court also discussed prior
case law establishing a cause
35
of action due to increased risk of harm.
Further, the court reasoned that an early warning is beneficial to
124. See Safer, 677 A.2d at 1190.
125. See id.
126. See id.
127. See id.
128. See id. at 1191 (noting the trial court's statement that Pate v. Threlkel,
640 So.2d 183 (Fla. Dist. Ct. App. 1994), was the only case "on point").
129. See Safer, 677 A.2d at 1190.
130. See id. at 1190-91.
131. See id.
132. See id. at 1192.
133. See id.
134. See id.
135. See id. at 1192 (citing Evers v. Dollinger, 471 A.2d 405 (N.J. 1984),
recognizing a cause of action for increased risk of harm).
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individuals at risk in preventing some of the consequences of the
disease."' Accordingly,
reasonable steps must be taken to inform the
-137
•
parties at risk.
However, the court did not define what constitutes
"reasonable steps," leaving unresolved the problem of how to limit
physician-patient confidentiality in certain circumstances.
The Safer Court broadened the physician's duty to warn to members of
the patient's immediate family.'39 In acknowledging this new duty, the
court allowed the privity requirement of the physician-patient relationship
to be superseded, suggesting a new legal standard for genetic testing. In
addition to judicial attempts to balance physicians' duty of confidentiality
against the duty to warn, legislators and regulators have also worked to
address this quandary.
B. Legislation and Regulations Addressing Disclosure of
Genetic Information

Public disclosure of one's genetic information may be harmful to that
individual. Possible negative results of disclosure include psychological,
social and financial injury as well as stigmatization, discrimination and
potential loss or difficulty in obtaining employment or insurance. 4' At
least thirty-one states have enacted legislation to protect the privacy of
genetic information in an effort to deter related discrimination.'42
One example of such legislation is Illinois' Genetic Information Privacy
Act.143 The primary objective of this legislation is to promote public
health by facilitating voluntary, confidential and nondiscriminatory use of

136. See id.
137. See id.
138. See id. at 1192.
139. See id. at 1192-93.

140. Burnett, supra note 48, at 575.
141. ASHG, supra note 6, at 478.
142. See Richard Saltus, Activists Renew Calls for Genetic Privacy Law, THE
BOSTON GLOBE, June 28, 2000, at Al (quoting Massachusetts State
Representative Jay R. Kaufman, "30 states have passed us by and already have

genetic privacy laws."). On August 22, 2000, Massachusetts became the 31" state

to pass a genetic privacy law, entering into law a bill protecting the privacy of
genetic test results and prohibiting employers and insurers from requiring such
tests (Act of Aug. 22, 2000, Ch.254, Mass. Acts of 2000).
143. Genetic Information Privacy Act, 410 ILL. COMP. STAT. 513 (1998).
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genetic testing information.'"
Included in the code is a section
recognizing exceptions• to
the
otherwise
confidential and privileged nature
141
of genetic information.
While permitting some exceptions, the statute
specifically states that these exemptions create neither an express nor
implied duty for the health care provider to notify the subject's spouse or
legal guardian of the test results.'"
So far, no federal legislation has been passed specifically relating to
genetic discrimination.'
However, on February 8, 2000, President
Clinton signed an executive order protecting federal employees from
discrimination in hiring or promotion actions.'"
In addition, some
existing federal anti-discrimination laws may be applicable to genetics. 49

144. See id. §5.
(2) Despite existing laws, regulations, and professional
standards which require or promote voluntary and confidential
use of genetic testing information, many members of the public
are deterred from seeking genetic testing because of fear that
test results will be disclosed without consent or be used in a
discriminatory manner.
145. See id. § 15 ("Except as otherwise provided in this Act, genetic testing
and information derived from genetic testing is confidential and privileged and
may be released only to the individual tested and to persons specifically
authorized, in writing in accordance with Section 30, by that individual to receive
the information.").
146. See id. § 30.
(a) No person may disclose or be compelled to disclose the identity of any
person upon whom a genetic test is performed or the results of a genetic
test ... except to the following persons:
The subject of the test or the subject's legally authorized representative.
This paragraph does not create a duty or obligation under which a health
care provider must notify the subject's spouse or legal guardian of the test
results, and no such duty or obligation shall be implied. No civil liability
or criminal sanction under this Act shall be imposed for any disclosure or
nondisclosure of a test result to a spouse by a physician acting in good
faith under this paragraph.
147. See Human Genome Project Information, GENETICS, PRIVACY AND
LEGISLATION, at http://www.ornl.gov/hgmis/project/about.htmi (last visited Dec.
18, 2001) (noting that several bills were introduced during the last decade, with the
primary public concern being discrimination by insurers and employers).
148. Id.
149. See generally The Americans with Disabilities Act of 1990 ("ADA"),
The Health Insurance Portability and Accounting Act of 1996 ("HIPAA"), and
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With respect to familial disclosure of genetic testing, The Medical Privacy
in the Age of Technologies Act of 1997"' permits health care providers to
notify a patient's family of genetic disease unless there is an express
instruction from the patient that such information remain confidential."'
However, this legislation does not require the physician to disclose
genetic information to a patient's children without his or her consent."'
Nevertheless, when a physician deems it necessary to inform a patient's
relative about the risk of a genetic disorder, an environment must exist in
which no detrimental consequences will result from the revelation of this
information. Thus, there is a need for set guidelines about how and when
disclosure of genetic data should occur.
IV. GUIDELINES FOR DISCLOSURE OF GENETIC INFORMATION TO
RELATIVES AT-RISK

Considering ethical and legal obligations, determinations about
whether to disclose
genetic information must be evaluated according to a
S
153
number of factors. While confidentiality should be respected, its scope
is not absolute.' 54 Competing interests may impose on physicians a duty to
warn relatives of their risk for genetically inherited disease.'
Accordingly, when reasonable efforts have failed to persuade the
patient to disclose information about genetically inheritable defects to
relatives, disclosure by the health care provider should be permissible if:
"(1)[t]here is [a] high risk of serious, imminent and foreseeable harm; (2)
[t]he at-risk relative(s) is (are) identifiable; (3) [t]he disease is
preventable, treatable or early monitoring will reduce the genetic risk; (4)
Title VII of the Civil Rights Act of 1964 ("Title VII").
150. H.R. 1815, 105th Cong. (1997).
151. See id.

152.
153.
154.
155.

[A] health care provider... may disclose protected health
information regarding an individual who is an inpatient in a
health care facility to individual's next of kin, to an individual
representative of the individual.. if (1) the individual who is
the subject of the information (A) has been notified of the
individual's right to object at the time of admission to the
facility and has not objected to the disclosure.
See id.
See id.
See id.
See id.
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[t]he harm of failing to disclose outweighs the harm of disclosure.'

56

A. High Risk of Serious, Imminent and ForeseeableHarm.

In Tarasoff, the California Supreme Court referred to protection of
"the threatened victim."'' 57 The Court also stated that disclosure was
unwarranted "unless such disclosure is necessary to avert danger to
others."'58 An individual refusing to disclose information to an at-risk
relative is, in effect, threatening the health of that relative if the danger
could be avoided by disclosure of that information. 9
The court in Pate expanded the physician's duty to warn, noting that 1a
patient's children do fall under the requisite zone of "foreseeable risk."'
Thus, the duty to warn may logically extend to physicians who possess
knowledge about a patent's refusal to inform relatives about genetic
information that is likely to be harmful to them.
B. The At-Risk Relative(s) Is (Are) Identifiable.

The Tarasoff court found that a duty to warn probably exists if the
physician has a special relationship with the person who may cause the
harm of the potential victim, the potential victim or person at risk is
identifiable, and the harm to the victim is foreseeable and serious."' The
court in Safer recognized that a physician owes a duty to communicate
about risk of disease to the patient as well as to members of the patient's
immediate family who may be adversely affected by a failure to warn.162
This conclusion differed from the court's determination in Pate that
directly warning at-risk relatives would be impractical and burdensome
for physicians."'
At-risk relatives possess genetic relatedness.16
Therefore if these
relatives are identifiable and reasonably reachable by the health care
156. See id.
157. Tarasoff, 551 P.2d at 347.
158. Id.

159. See Jennifer Miller, Physician-PatientConfidentialityand FamilialAccess
to Genetic Information, 2 HEALTH L. J. 141, 149 (1994).

160. Pate, 661 So.2d at 282.
161. Tarasoff, 551 P.2d at 450.

162. Safer, 677 A.2d at 1192.
163. Pate, 661 So.2d at 282.
164. ASHG, supra note 6.
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professional, these at-risk relatives deserve to be warned of possible
disease.
C. The Disease Is Preventable, Treatableor Early Monitoring Will
Reduce the Genetic Risk.
While analysis of Tarasoff arguably supports finding a duty to warn atrisk relatives about potential genetic risk, legal scholars have
distinguished its applicability in the two situations. These commentaries
interpret differences in the nature of the harm. 166 They argue that in cases
161
of threats of violence, it is the patient's actions that cause the harm.
With genetic conditions, however, the patient is not placing relatives at
risk by carrying the gene mutation since, regardless of the patient's
actions, the relatives will either posses or not posses the mutation.6 6
However, this reasoning does not hold when the genetic risk is
preventable, treatable, or early monitoring reduces its ill effects. In such
cases, warning the at-risk relative is not futile. Instead, providing the
relative notice of his or her possible disease can only aid in preventing
harm. This provides a responsible and benevolent approach to handling
such information.
D. The Harm of Failing to Disclose Outweighs the Harm of
Disclosure.
In Safer,
the New Jersey Supreme Court applied the infectious disease
169
model. The court held that no significant difference existed between the
165. Miller, supra note 157, at 148 (discussing the positions taken by L.B.
Andrews in MEDICAL GENETICS: A LEGAL FRONTIER 188 (1987) and J.K.M.
Gevers in Genetic Testing: The Legal Position of Relatives of Test Subjects, 7 MED.
&

LAW

161,163 (1988)).

166. ASHG, supra note 6, at 479 (citing Suter, supra note 88, and Miller,
supra note 157,
[W]ho point out that there are number of similarities between
the two cases: a special relationship exists between the
physician and the patient, the third party is identifiable, there is
no special relationship between the physician and the third
party, the information to be disclosed is confidential, and there
is an opportunity for the prevention of harm.
167. Id.
168. See id.
169. Safer, 677 A.2d at 1192.
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threat of infection and the threat posed
•• 170 by a genetic disease when a
physician fails to disclose the condition.
The court also noted that the
genetic risks are as foreseeable as infectious ones and that "[t]he
individual or group at risk is easily identified, and substantial future harm
7
is easily identified or minimized by a timely and effective warning."' '
Disclosure of communicable disease is allowable because society's
welfare is protected through warnings about the risk of infection.'72 As
with disclosure of contagious disease, disclosure of harmful genetic
information may serve an overriding public interest. When disclosure will
prevent or lessen the harm caused by genetic defect, it should be
permissible.
CONCLUSION
The confidentiality requirement of the physician-patient relationship is
sacred. Unrestrained use of an individual's genetic information could
result in denial of employment, mortgages, pensions, loans and life
insurance.173 Thus, the privacy of medical information should be
respected. However, certain situations warrant a physician's breach of the
confidentiality of his or her patient's medical information. In these cases,
physicians may disclose patient information to at-risk third parties in an
attempt to warn them of adverse consequences. Such action is justified to
prevent harm if the harm in failing to disclose outweighs the harm of
disclosure. Factors to consider in this balancing include the relative's
likelihood of developing the disease, the severity of the disease, and the
ability to prevent or treat the disease. Additionally, the provider should
take into account the patient's reaction, considering his or her mental and
physical well being. Many of these patients are already under great stress
and such a revelation may exacerbate their anxiety. Accordingly, a
support mechanism may need to be in place.
New developments in genetic testing allow for increased forewarning of
possible harms based on genetic information.
Disclosure of this
information could possibly prevent harm or help those at-risk of harm.
Optimally, physicians need only explain such risks to patients, who in turn
will warn their at-risk relatives. However, when patients fail to do so,

170. See id.

171. Id. at 1192.
172. See supra text accompanying note 64.
173. McGleenan, supra note 28, at 51.
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courts in some cases are willing to extend a physician's privilege to warn
third parties when the matter involves relatives at-risk for genetically
inheritable disease.
Finally, as suggested in Tarasoff,the duty to disclose must be narrowly
tailored. Thus, more specific guidelines should be drawn as to when
certain genetic predispositions may or may not be disclosed. This would
allow for some consistency in the medical community and help avoid
charges of unnecessary disclosure. However, as the disclosure of any
medical information is inconsistent with the medical ethic, we should be
careful to carve out only the narrowest exceptions necessary to achieve
the desired goal.

